How many insider trades does FilingIQ track for EDSA?

FilingIQ tracks 132 Form 4 insider transactions for EDSA (Edesa Biotech, Inc.), covering filings from Jun 7, 2019 onwards. 12 of those were filed in the last 90 days.

Are EDSA insiders net buyers or net sellers?

Across the full Form 4 history for EDSA, 47 transactions (36%) were open-market purchases and 7 (5%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does EDSA insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is EDSA in?

Edesa Biotech, Inc. (EDSA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $8.92M.

EDSA insider trading

Healthcare

Edesa Biotech, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

132

Last 90 days

Buys / sells

36% / 5%

Market cap

$8.92M

About Edesa Biotech, Inc.

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis. The company develops EB07, a monoclonal antibody, which is in a Phase 2 clinical study for the treatment of pulmonary fibrosis; and EB06, a human monoclonal antibody candidate that binds to chemokine ligand 10 (CXCL10) and inhibits the interaction of CXCL10 with its receptors, CXCR3A, and CXCR3B. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

Company website: www.edesabiotech.com

EDSA insider activity at a glance

FilingIQ has scored 132 insider transactions for EDSA since Jun 7, 2019. The most recent filing in our index is dated Apr 1, 2026.

Across the full history, 47 open-market purchases and 7 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on EDSA insider trades is 59.1/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live EDSA trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for EDSA?: FilingIQ tracks 132 Form 4 insider transactions for EDSA (Edesa Biotech, Inc.), covering filings from Jun 7, 2019 onwards. 12 of those were filed in the last 90 days.
Are EDSA insiders net buyers or net sellers?: Across the full Form 4 history for EDSA, 47 transactions (36%) were open-market purchases and 7 (5%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does EDSA insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is EDSA in?: Edesa Biotech, Inc. (EDSA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $8.92M.

Methodology & sources

Every EDSA insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.